Claritev Corporation Announces Pricing of Offering of Class A Common Stock by Selling Stockholders

Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the pricing of an underwritten public offering (the “Offering”) of 1,500,000 shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), by certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”) at a price to the public of $51.50 per share. The Selling Stockholders granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of Class A common stock. The underwriters propose to offer the shares of Class A common stock to the public at a fixed price, which may be changed at any time without notice. Claritev will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholders. The Offering is expected to close by November 14, 2025, subject to customary closing conditions.

Barclays, Guggenheim Securities and Wells Fargo Securities are acting as joint-lead bookrunning managers for the Offering. Citigroup and Piper Sandler are acting as additional bookrunners for the Offering. The Offering may be made only by means of a prospectus supplement and accompanying prospectus. Claritev has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the Offering. A prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website. Before you invest, you should read the prospectus supplement and accompanying prospectus and other documents Claritev has filed with the SEC for more complete information about Claritev and the Offering. You may get these documents for free, once available, by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Barclays, Guggenheim Securities or Wells Fargo Securities will arrange to send you the prospectus supplement and accompanying prospectus relating to the Offering if you contact Barclays Capital Inc. at c/o Broadridge Financial Solutions, 1155 Long Island Avenue Edgewood, NY 11717, by telephone at [phone], or by email at [e-mail]; Guggenheim Securities, LLC at 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, by telephone at [phone], or by email at [e-mail]; or Wells Fargo Securities, LLC at 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, Attention: Wells Fargo Securities, by telephone at [phone] (option #5) or by email at [e-mail].